L-Leucine-13C6,15N|CAS 202406-52-8|DC Chemicals

Cas No.:	202406-52-8
Chemical Name:	L-Leucine-13C6,15N
Formula:	₁₃C₆H₁₅Cl₁₅N₄O₂
M.Wt:	138.12
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC47561	MHY-1685	MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.
DC11816	RapaLink-1	RapaLink-1 is a third-generation mTOR inhibitor that overcomes resistance to existing first- and second-generation inhibitors; blocks mTOR signaling of the F2108L mTOR and M2327I mTOR drug resistant mutants; RapaLink-1 is more potent mTOR inhibitor than rapamycin.
DC1006	OSI-027	OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively.
DC7210	LY-303511(Nv-128)	LY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K.
DC7171	INK-128(Sapanisertib)	INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms.
DC11866	AZD 3147	A potent, selective dual mTORC1 and mTORC2 inhibitor with enzyme IC50 of 1.5 nM.
DC77105	YB-3-17	YB-3−17 is a dual-target compound that effectively and selectively inhibits mTOR with an IC50 of 0.22 nM, while promoting GSPT1 degradation with an IC50 of 5 nM, leading to substantial tumor growth inhibition both in vitro and in vivo. It also exhibits significant antiproliferative activity in glioblastoma models.
DC77104	PD-M6	PD-M6 is an mTOR PROTAC degrader (DC50: 4.8 μM). PD-M6 promotes the ubiquitination and degradation of mTOR. PD-M6 inhibits the proliferation of HeLa, MCF-7, and HepG2 cancer cell lines (IC50 values of 11.3, 2.58, and 3.23 μM, respectively) and induces autophagy. PD-M6 specifically induces the degradation of LAMTOR1, a key protein in the mTOR signaling pathway.
DC77103	HYS-072	HYS-072 is an orally active derivative of chrysin.
DC77102	AV457	AV457 is a potent and selective mTOR inhibitor with an IC50 value of 0.54 µM. AV457 inhibits cyst growth in polycystic kidney disease (PKD) organoids. AV457 decreases the protein expression of P-s6, P-p70s6 and don’t decreases the protein expression of P-AKT.